APOLLOMICS INC.C.A DL-,01

Apollomics replaces the resigned Po‑Jen Hsueh with Dr. Ya‑Chi (Claudia) Huang, who also joins the audit committee and the nominations and corporate governance committee. The biopharmaceutical company plans major restructurings: the dismissal of all U.S. staff including the CEO and CFO, the termination of the clinical SPARTA study and preparation for a shareholder vote on a possible wind‑down. Analysts point to recent strong share gains, a valuation of about USD 46 million, favorable liquidity metrics relative to debt but high cash burn, and expected revenue growth alongside a declining net result. » Más en de.investing.com